WO2018183454A1 - Méthode et dispositif de diagnostic précis de maladies dentaires - Google Patents

Méthode et dispositif de diagnostic précis de maladies dentaires Download PDF

Info

Publication number
WO2018183454A1
WO2018183454A1 PCT/US2018/024779 US2018024779W WO2018183454A1 WO 2018183454 A1 WO2018183454 A1 WO 2018183454A1 US 2018024779 W US2018024779 W US 2018024779W WO 2018183454 A1 WO2018183454 A1 WO 2018183454A1
Authority
WO
WIPO (PCT)
Prior art keywords
atps
porous material
concentration
analyte
solution
Prior art date
Application number
PCT/US2018/024779
Other languages
English (en)
Inventor
Yin To CHIU
Original Assignee
Chiu Yin To
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiu Yin To filed Critical Chiu Yin To
Publication of WO2018183454A1 publication Critical patent/WO2018183454A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/18—Dental and oral disorders

Definitions

  • the present invention relates to a method and device for improving detection accuracy and diagnostic performance.
  • the method is related to components of ATPS (aqueous two-phase system) which are embedded entirely within a porous material, allowing spontaneous phase separation and therefore, purification and concentration of analytes with only a single- step required from the end user.
  • ATPS aqueous two-phase system
  • the present invention further provides a diagnostic detection device for carrying out the method of the present invention.
  • the analyte can be a biomarker of a disease such as a cell free DNA (cfDNA), circulating tumor DNA (ctDNA) or a protein which may exist in a sample such as saliva, blood, urine and other bodily fluids of the patient.
  • cfDNA cell free DNA
  • ctDNA circulating tumor DNA
  • Many of the existing diagnostic or detection methods may falsely report that the analyte does not exist if the analyte concentration is too low.
  • the gold standard of diagnostics such as Polymerase Chain Reaction (PCR) and Enzyme- Linked Immune Sorbent Assay (ELIS A) may produce a false negative result if the targeted analyte has extremely low concentration.
  • cfDNA Cell free DNA extracted from liquid biopsies has become an attractive biomarker for several pathologic conditions.
  • cfDNA likely released from apoptotic or necrotic tumor cells can be used to monitor cancer progression and relapse throughout treatment with potentially greater sensitivity than current gold standard imaging methods like Computed Tomography (CT), Positron Emission Tomography (PET), and Magnetic Resonance Imaging (MRI).
  • CT Computed Tomography
  • PET Positron Emission Tomography
  • MRI Magnetic Resonance Imaging
  • liquid biopsies are noninvasive, can be collected at multiple time points, and can yield cfDNA that better represents the diversity of the tumor, which is useful for identifying drug-resistant mutations.
  • cfDNA of the fetus can indicate various abnormalities during pregnancy such as aneuploidies, which can be done earlier than current prenatal testing methods like chorionic villi sample and amniocentesis, without the risk of spontaneous abortion.
  • Liquid biopsies of heart transplant patients can reveal donor cfDNA, which can be a warning sign that the patient will reject the transplant in the upcoming weeks or months after the transplant.
  • the present invention provides an improved method and device to purify target analytes from samples and concentrate the purified target analytes for further analysis, the above can be easily and quickly done in a single step without the need of complex equipment.
  • the present methods and devices can concurrently perform a number of tasks including cell lysis, isolating targeted biomolecules, removing non-targeted biomolecules and impurities, and concentrating targeted biomolecules. Concentrating biomolecules or removing inhibitors will improve detection accuracy and diagnostic performance.
  • the present method and device can purify target analytes from samples and concentrate them for up to lOOx or more.
  • the methods and device described herein can improve the accuracy, sensitivity and efficiency of the detection and quantification of biomolecules and therefore are capable of improving the performance of various analytical or diagnostic technologies relying on the detection and/or quantification of biomolecules. Many life-threatening diseases are cured if the diseases are detected early.
  • the present invention relates to an improved method and device for improving detection accuracy and diagnostic performance.
  • the present method and device is related to components of ATPS (aqueous two-phase system) which are embedded entirely within a porous material, allowing spontaneous phase separation and therefore, purification and concentration of analytes with only a single-step required from the end user.
  • ATPS aqueous two-phase system
  • the present invention provides a method and device for concentration and detection of a target analyte in a solution using a pre-coated porous material embedded with ATPS components.
  • the porous material is pre-coated with water soluble nanoparticles.
  • the water soluble nanoparticles include, but are not limited to, silicon dioxide, iron oxide, titanium dioxide, silver oxide and any combinations thereof.
  • the present invention provides a device comprising ATPS as a concentration module linked with a lateral flow immunoassay (LFA) component as a detection module.
  • the detection module is housed in a plastic housing with a viewing window and gold nanoprobes. As the sample wicks up the device and ATPS components undergo phase separation, the analytes are concentrated substantially in the leading front. Concentrated analytes are then detected by the LFA module generating visual test results.
  • Figure 1 shows phase separation within different porous materials embedded with two- component ATPS.
  • the pre-coated porous materials used include fiberglass paper (FG), cotton- based paper (C), single-layer matrix paper (SM) and polyolefin foam pad (PO) from 3 different vendors.
  • Figure 2 shows a schematic diagram of the present device where the analytes are concentrated in the leading front of the fluid flow and detected, generating visual test results.
  • FIG 3 shows one embodiment of the present invention in which biomolecules were concentrated in the leading front of the ATPS on the porous material up to various concentration factors.
  • Figure 4 shows concentration of biomolecules from different types of sample (urine and saliva) using the present pre-coated porous material embedded with ATPS components.
  • Figure 5 shows that the present device comprising a porous material embedded with two- component ATPS enhance the sensitivity of detecting S. mutans.
  • the result demonstrates a 100- fold improvement in the limit of detection of S. mutans over detection using LFA module alone
  • Figure 6 shows various designs of the present device using porous material with embedded two-component ATPS as a concentration module.
  • Figure 7 illustrates one embodiment of the manufacturing process of a concentration module.
  • Figure 8 demonstrates the feasibility of changing the placement and ordering of ATPS components on the concentration module.
  • Figure 9 shows various designs of the present device.
  • Figure 9A shows a closed (assembled) and an open configuration of a vertically oriented cassette housing design for the present device which contains sample in a separate well component.
  • Figure 9B shows a closed (assembled) and an open configuration of a vertically oriented cassette housing design for the present device which contains sample in an integrated well component.
  • Figure 9C shows a closed (assembled) and an open configuration of a horizontally oriented cassette housing design for the present device which allows sample to be added from above the test strip.
  • Figure 9D shows a closed (assembled) and an open configuration of a horizontally oriented cassette housing design for the present device which allows sample to be added from below the test strip.
  • Figure 10 shows several CAD models of cassette housing designs for the present device.
  • the present invention relates to an improved method and device for improving detection accuracy and diagnostic performance.
  • the present method and device is related to components of ATPS (aqueous two-phase system) which are embedded entirely within a porous material, allowing spontaneous phase separation and therefore, purification and concentration of analytes with only a single-step required from the end user.
  • ATPS aqueous two-phase system
  • the present invention provides a method and device for concentration and detection of a target analyte in a solution using a pre-coated porous material embedded with ATPS components.
  • the porous material is pre-coated with water soluble nanoparticles.
  • the water soluble nanoparticles include, but are not limited to, silicon dioxide, iron oxide, titanium dioxide, silver oxide and any combinations thereof.
  • the present invention provides a device comprising ATPS as a concentration module linked with a lateral flow immunoassay (LFA) component as a detection module.
  • the detection module is housed in a plastic housing with a viewing window and gold nanoprobes. As the sample wicks up the device and ATPS components undergo phase separation, the analytes are concentrated extremely in the leading front. Concentrated analytes are then detected by the LFA module generating visual test results.
  • the present invention provides a method that improves the performance of various detection and diagnostic techniques, for example, in terms of accuracy, sensitivity and efficiency.
  • the present invention further provides a diagnostic or detection device for carrying out the methods described herein.
  • the present method and device can separate a target analyte from non-target molecules (e.g., small molecules and macromolecules which are typically of natural origin and may interfere with the detection or quantification of target analyte) in a sample and thereby allows a more accurate detection and diagnosis.
  • non-target molecules e.g., small molecules and macromolecules which are typically of natural origin and may interfere with the detection or quantification of target analyte
  • samples include but are not limited to blood, plasma, serum, tissues, bacteria, viruses, RNA viruses, smear preparations, bacteria cultures, cell cultures (e.g. cell suspensions and adherent cells), urine, saliva, fecal matters, and bodily discharges (e.g. tears, sputum, nasopharyngeal mucus, vaginal discharge and penile discharge), polymerase chain reaction (PCR) mixtures and in vitro nucleic acid modification reaction mixtures.
  • PCR polymerase chain reaction
  • the present method and device are used to purify and concentrate a target analyte from blood.
  • the present method is able to lyse the blood cells to release their contents, separate the target analyte from non-target molecules including cell debris, and concentrate the target analyte simultaneously.
  • the present method and device are used to purify and concentrate a target biomarker from saliva or urine.
  • the present invention was applicable to urine and saliva.
  • the concentration phenomenon behaved similarly to PBS.
  • the porous materials can filter out any large molecules that would disrupt the LFA performance.
  • the target analytes include but are not limited to proteins, nucleic acids, carbohydrates, lipids, bacteria, virus and nanoparticles and the like.
  • the target analyte is a cell-free molecule including but is not limited to a cell-free DNA (cfDNA), a cell-free protein, an exosome and a cell-free molecule circulating in the body fluid of the subject.
  • the biomarker is a molecule attached to the surface of a cell, or included in a cell.
  • the target analyte is a nucleic acid of various types (e.g. DNA including cDNA, RNA including mRNA and rRNA), forms (e.g. single- stranded, double-stranded, coiled, as a plasmid, non-coding or coding) and lengths (e.g. an oligonucleotide, a gene, a chromosome and genomic DNA), originated from the subject or an exogenous agent or both.
  • DNA including cDNA
  • RNA including mRNA and rRNA forms
  • forms e.g. single- stranded, double-stranded, coiled, as a plasmid, non-coding or coding
  • lengths e.g. an oligonucleotide, a gene, a chromosome and genomic DNA
  • the target analyte is a protein which is a peptide or a polypeptide, including an intact protein molecule, a degraded protein molecule and digested fragments of a protein molecule.
  • biomarkers include but are not limited to antigens, receptors and antibodies, originated from the subject or an exogenous agent or both.
  • the target analyte is a small molecule such as a metabolite.
  • the metabolite is a disease-related metabolite which is indicative of the presence or extent of a disease or a health condition.
  • the metabolite is a drug-related metabolite such as a drug by-product of which the level changes in a subject body consuming the drug.
  • the target analyte is originated from the subject himself or herself (e.g. molecules that are derived or released from any organs, tissues or cells of the subject), an exogenous source (e.g. a pathogen such as virus or bacteria associated with a particular disease), or a food or drug taken by the subject.
  • the target analyte is a molecule produced by a tumor or cancer, or by the body of the subject in response to a tumor or cancer.
  • the target analyte is not normally found in healthy subject.
  • the target biomarker is a molecule that is normally found in a healthy subject but the level of which is indicative of a particular disease or a health condition.
  • a two-component ATPS aqueous two phase system embedded entirely within a porous material for purifying a target analyte from a sample and concentration of the target analyte.
  • the ATPS components are embedded entirely within a porous material, allowing spontaneous phase separation and therefore, purification and concentration of analytes with only a single-step required from the end user.
  • a two-component ATPS is embedded entirely within a porous material which is pre-coated with water soluble nanoparticles.
  • the two phases of the ATPS separate from each other as the mixed phase solution flows through the porous materials.
  • the resulting phase solutions are of different physicochemical properties and each phase travels through the porous matrix at different rates. Different molecules in a mixture would be distributed differentially between the two phase solutions due to their different properties, and it is possible to separate and concentrate target molecules using ATPS with minimal set up and human intervention. No power or equipment is necessary to bring about the phase separation, as the fluid flow relies purely on capillary action which is based on isothermal-dynamic principles.
  • the advantage of the invention is that high purity and concentration of the target analyte can be obtained in a simple way and compatible with downstream application analysis without further step of purification or concentration.
  • the methods and devices provided herein are robust, inexpensive, simple, easy to handle, safe, user friendly and fast.
  • the present method and device is able to purify and concentrate the target analyte and thereby ensures the performance of the downstream applications using the purified and concentrated analyte will not be affected by impurities in the original sample. Since the present invention does not require any additional power source, complex instrumentation or electronic hardware to operate, it provides a fast and affordable means for rapid analyte isolation and purification.
  • the present invention can purify and concentrate the target analyte conveniently and rapidly without the use of external power source or complex instrumentation, and is applicable to samples containing the target analyte in a very low amount, or of a small volume. Furthermore, the present method is readily adaptable to automation including high throughput screening systems.
  • the present invention provides a porous material embedded with ATPS components.
  • Various ATPS systems can be used in the present invention, including but are not limited to polymer-polymer (e.g.PEG-dextran), polymer-salt (e.g. PEG-salt), and micellar (e.g. Triton X-114).
  • Porous material may be made of any suitable porous material which can absorb and transfer liquid. Suitable porous materials for this invention include but are not limited to fiberglass paper, cotton-based paper, other types of paper, polymer foams, cellulose foams, other types of foams, rayon fabric, cotton fabric, other types of fabric, wood, stones, and any other materials that can absorb and transfer liquid.
  • the porous material is commercially available or manufactured in- house.
  • Figure 1 illustrates the ability of several types of porous materials (fiberglass paper, cotton- based paper, single-layer matrix paper and polyolefin foam pad) from three vendors in inducing phase separation when impregnated with ATPS components. Target analytes were indicated by a purple color. As shown in Figure 1, fiberglass paper FGl from vendor 1, FGl and FG2 from vendor 2 and polyolefin foam pad from vendor 3 were the best at concentrating analyte with a strong leading purple front.
  • porous materials fiberglass paper, cotton- based paper, single-layer matrix paper and polyolefin foam pad
  • the present invention provides a method and device for concentration and detection of a target analyte in a solution using a pre-coated porous material embedded with ATPS components.
  • the present invention provides a porous material that is pre-coated with water soluble nanoparticles and embedded with ATPS components.
  • the pre-coated porous material is capable of increasing the concentration of target analyte significantly by enhancing the adhesion property and facilitating the embedding of ATPS on the porous material.
  • the present porous material is pre-coated with water soluble nanoparticles.
  • the water soluble nanoparticles include, but are not limited to, silicon dioxide, iron oxide, titanium dioxide, silver oxide and any combinations thereof.
  • the porous material comprises a surface and plurality of pores/capillary system.
  • the surface of the porous material is pre-coated with water soluble nonparties.
  • pores/capillary system of the porous material are pre-coated with water soluble nonparties.
  • both the surface and pores/capillary system of the porous material are pre-coated with water soluble nonparties.
  • both the surface and pores/capillary system of the porous material are pre-coated with silicon dioxide.
  • Water soluble nanoparticles e.g. silicon dioxide
  • carry both positive and negative charges which play an important role to influence the interaction between the molecules in ATPS and the porous material.
  • pre-coating the porous material with water soluble nanoparticles significantly facilitates the efficient of embedding of ATPS on the porous material. With better embedding, ATPS is more stable on the porous material and ultimately improve the concentration performance.
  • concentration fold achieved by this invention can be up to 100 or more.
  • porous material for example, porous fiberglass paper
  • porous fiberglass paper is coated with addition of water soluble nanoparticles, such as silicon dioxide, by the following preparation process: 5M concentration of silicon dioxide is dispersed in aqueous solution. Porous fiberglass paper is soaked in the 5M silicon dioxide aqueous solution followed by the vigorous stirring for an hour. The system is kept at the temperature of 80°C for 24 hours. Then the paper is taken out and washed twice with water, and finally dried under compressed air.
  • the relative amounts of ATPS components in the porous material can be changed.
  • the target analyte can be preferentially concentrated in one phase.
  • the target analyte is retained in the leading front of the ATPS, which is then collected and optionally further analyzed using appropriate technologies.
  • target analyte is purified at the top of the porous material embedded with ATPS components and concentrated for up to 50-100 folds as compared to a control stack having no ATPS components.
  • the order of ATPS components on the porous material can be adjusted to achieve the desired phenomenon.
  • one or more components can be embedded onto the porous material.
  • an assay was developed to evaluate the correlation between the relative amounts of ATPS components embedded on the porous material and the fold of concentration achieved. With this, the concentration factor can be selected and fine-tuned by adjusting the relative amount of the ATPS components as needed.
  • the ATPS components were solubilized in water (or appropriate buffer) and applied on the porous material in certain ratios.
  • the porous materials were then placed in a lyophilizer to remove water, resulting in the ATPS components embedded directly on the porous material.
  • the ATPS components instantly undergo rehydration and thereby separate the molecules in the sample and concentrate the target analyte at the front of the fluid flow without any external power or equipment to provide a driving force.
  • the data herein demonstrated that by adjusting the ratios of ATPS components embedded on the porous material, the present invention can adjust the concentration factor as needed. Furthermore, the data indicated that multiple ATPS components (a polymer/salt system and micellar system) incorporated into porous material can achieve purification and concentration of analyte. Other polymer/salt, micellar, and polymer/polymer systems can be likewise implemented with further optimization.
  • the present invention provides a device comprising a porous fiberglass paper that is impregnated with ATPS which is made of polymer to polymer-based PEG-dextran.
  • ATPS which is made of polymer to polymer-based PEG-dextran.
  • the impregnated porous fiberglass paper preferentially causes the analyte-containing ATPS component to flow ahead of the other ATPS component. Therefore, the targeted analyte is concentrated in the analyte-containing ATPS component at the front of the fluid flow.
  • the present invention provides a device comprising a porous fiberglass paper that is pretreated with ATPS which is made of polymer to salt based PEG-salt.
  • ATPS which is made of polymer to salt based PEG-salt.
  • the pretreated porous fiberglass paper preferentially causes the analyte-containing ATPS component to flow ahead of the other ATPS component. Therefore, the targeted analyte is concentrated in the analyte-containing ATPS component at the front of the fluid flow.
  • the present invention provides a device comprising a porous fiberglass paper is impregnated with ATPS which is made of micellar based surfactant-containing solutions.
  • ATPS which is made of micellar based surfactant-containing solutions.
  • the impregnated porous fiberglass paper preferentially causes the analyte-containing ATPS component to flow ahead of the other ATPS component. Therefore, the targeted analyte is concentrated in the analyte-containing ATPS component at the front of the fluid flow.
  • sample subject to the present invention comprises a buffer solution includes, but are not limited to, phosphate-buffered saline (PBS), Tris-EDTA (TE) buffer.
  • PBS phosphate-buffered saline
  • TE Tris-EDTA
  • prefer buffer is PBS buffer 9.57 Mm (8 mM Sodium chloride, 0.2 mM Potassium chloride, 1.15 mM Sodium monohydrogen phosphate, 0.2 mM Potassium dihydrogen phosphate, solution with pH 7.35-7.65).
  • the buffer is TE buffer containing 2% bovine serum albumin (BSA), 0.1% Tween-20, 0.1%PEG and 20 mM Tris, pH 7.5 respectively.
  • BSA bovine serum albumin
  • multiple ATPS are incorporated into a porous material to achieve a control of concentration factors of the target analyte.
  • a polymer/salt ATPS is implemented with the optimization in the ratios of the ATPS components to control the concentration factors.
  • a polymer/polymer ATPS is implemented with the optimization in the ratios of the ATPS components to control the concentration factors.
  • micellar ATPS is implemented with the optimization in the ratios of the ATPS components to control the concentration factors.
  • the ratios of the ATPS components are adjusted to demonstrate concentration factors between 10 folds and 100 folds.
  • ATPS systems including but not limited to polymer- polymer (e.g., PEG-dextran), polymer-salt (e.g. PEG-salt), and micellar (e.g. Triton X-114).
  • the first and/or second component comprises a polymer.
  • Polymer includes but is not limited to polyalkylene glycols, such as hydrophobically modified polyalkylene glycols, poly (oxy alky lene)polymers, poly(oxyalkylene)copolymers, such as hydrophobically modified poly(oxyalkylene)copolymers, polyvinyl pyrrolidone, polyvinyl alcohol, polyvinyl caprolactam, polyvinyl methylether, alkoxylated surfactants, alkoxylated starches, alkoxylated cellulose, alkyl hydroxyalkyl cellulose, silicone-modified polyethers, and poly N-isopropylacrylamide and copolymers thereof.
  • the first polymer comprises polyethylene glycol, polypropylene glycol, or dextran.
  • the polymer concentration of the first component or second component is in the range of about 0.01% to about 90% by weight of the total weight of the aqueous solution (w/w).
  • the polymer solution is selected from a polymer solution that is about 0.01% w/w, about 0.05% w/w, about 0.1 % w/w, about 0.15% w/w, about 0.2% w/w, about 0.25% w/w, about 0.3% w/w, about 0.35% w/w, about 0.4% w/w, about 0.45% w/w, about 0.5% w/w, about 0.55% w/w, about 0.6% w/w, about 0.65% w/w, about 0.7% w/w, about 0.75% w/w, about 0.8% w/w, about 0.85% w/w, about 0.9%) w/w, about 0.95% w/w, or about 1% w/w.
  • the polymer solution is selected from polymer solution that is about 1% w/w, about 2% w/w, about 3% w/w, about 4% w/w, about 5% w/w, about 6% w/w, about 7% w/w, about 8% w/w, about 9% w/w, about 10% w/w, about 1 1% w/w, about 12% w/w, about 13% w/w, about 14% w/w, about 15% w/w, about 16% w/w, about 17% w/w, about 18% w/w, about 19% w/w, about 20% w/w, about 21% w/w, about 22% w/w, about 23% w/w, about 24% w/w, about 25% w/w, about 26% w/w, about 27% w/w, about 28% w/w, about 29% w/w, about 30% w/w, about 31
  • the first and/or second component comprises a salt
  • the salt includes but is not limited to kosmotropic salts, chaotropic salts, inorganic salts containing cations such as straight or branched trimethyl ammonium, triethyl ammonium, tripropyl ammonium, tributyl ammonium, tetramethyl ammonium, tetraethyl ammonium, tetrapropyl ammonium and tetrabutyl ammonium, and anions such as phosphates, sulphate, nitrate, chloride and hydrogen carbonate.
  • the salt is selected from the group consisting of NaCl, Na3P04, K3P04, Na2S04, potassium citrate, (NH4)2S04, sodium citrate, sodium acetate and combinations thereof.
  • Other salts e.g. ammonium acetate, may also be used.
  • the total salt concentration is in the range of 0.001 mM to lOOmM.
  • the amount of salt needed to form an aqueous two- phase system will be influenced by molecular weight, concentration and physical status of the polymer.
  • the salt phase is selected from a salt solution that is about 0.001% to 90% w/w.
  • the salt solution is selected from a salt solution that is about 0.01% w/w, about 0.05% w/w, about 0.1 % w/w, about 0.15% w/w, about 0.2% w/w, about 0.25% w/w, about 0.3% w/w, about 0.35% w/w, about 0.4% w/w, about 0.45% w/w, about 0.5% w/w, about 0.55% w/w, about 0.6% w/w, about 0.65% w/w, about 0.7% w/w, about 0.75% w/w, about 0.8% w/w, about 0.85% w/w, about 0.9%) w/w, about 0.95% w/w, or about 1% w/w.
  • the salt solution is selected from polymer solution that is about 1% w/w, about 2% w/w, about 3% w/w, about 4% w/w, about 5% w/w, about 6% w/w, about 7% w/w, about 8% w/w, about 9% w/w, about 10% w/w, about 1 1% w/w, about 12% w/w, about 13% w/w, about 14% w/w, about 15% w/w, about 16% w/w, about 17% w/w, about 18% w/w, about 19% w/w, about 20% w/w, about 21% w/w, about 22% w/w, about 23% w/w, about 24% w/w, about 25% w/w, about 26% w/w, about 27% w/w, about 28% w/w, about 29% w/w, about 30% w/w, about 31
  • the first component and/or the second component in the ATPS comprises a solvent that is immiscible with water.
  • the solvent comprises a non-polar organic solvent.
  • the solvent comprises an oil.
  • the solvent is selected from pentane, cyclopentane, benzene, 1,4- dioxane, diethyl ether, dichloromethane, chloroform, toluene and hexane.
  • the first component and/or second component in the ATPS comprises a micellar solution.
  • the micellar solution comprises a nonionic surfactant.
  • the micellar solution comprises a detergent.
  • the micellar solution comprises Triton-X.
  • the micellar solution comprises a polymer similar to Triton-X, such as Igepal CA-630 and Nonidet P-40.
  • the micellar solution consists essentially of Triton-X.
  • the first component in the ATPS comprises a micellar solution and the second component in the liquid phase comprises a polymer.
  • the second component in the liquid phase comprises a micellar solution and the first component in the liquid phase comprises a polymer.
  • the first component in the liquid phase comprises a micellar solution and the second component in the liquid phase comprises a salt.
  • the second component in the liquid phase comprises a micellar solution and the first component comprises a salt.
  • the micellar solution is a Triton-X solution.
  • the first component comprises a first polymer and the second component comprises a second polymer.
  • the first/second polymer is selected from polyethylene glycol and dextran.
  • the first component comprises a polymer and the second component comprises a salt. In one embodiment, the second component comprises a polymer and the first component comprises a salt. In some embodiments, the first component comprises polyethylene glycol and the second component comprises potassium phosphate. In some embodiments, the second component comprises polyethylene glycol and the first component comprises potassium phosphate. In one embodiment, the first component comprises a salt and the second component comprises a salt. In one embodiments, the first component comprises a kosmotropic salt and the second component comprises a chaotropic salt. In some embodiments, the second component comprises a kosmotropic salt and the first component comprises a chaotropic salt.
  • ratios of the first component to the second component are in the range of 1: 1 to 1: 1000.
  • the ratio of the first component to the second component is selected from a ratio of about 1: 1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, and about 1: 10.
  • the ratio of the first component to the second component is selected from a ratio of about 1:20, about 1:30, about 1:40, about 1:50, about 1:60, about 1:70, about 1:80, about 1:90, and about 1: 100.
  • the ratio of the first component to the second component is selected from a ratio of about 1:200, about 1:300, about 1:400, about 1:500, about 1:600, about 1:700, about 1:800, about 1:900, and about 1: 1000.
  • the ratio of the second component to the first component is selected from a ratio of about 1: 1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, and about 1: 10. In some embodiments the ratio of the second component to the first component is selected from a ratio of about 1:20, about 1:30, about 1:40, about 1 :50, about 1:60, about 1:70, about 1:80, about 1:90, and about 1: 100.
  • the ratio of the second component to the first component is selected from a ratio of about 1:200, about 1:300, about 1:400, about 1:500, about 1:600, about 1:700, about 1:800, about 1:900, and about 1: 1000.
  • the present invention can be used in combination with one or more processes or reagents for the purpose of washing and elution of the analytes retained in the porous matrix, or post-isolation treatment of the retained analytes.
  • washing buffer is applied on the ATPS, once or for multiple times, to wash off non-target analytes or impurities from the porous matrix.
  • Washing buffers may comprise solutions of varying ionic strength, pH values, or contain additives such as detergents.
  • Examples of washing buffers include but are not limited to a solution of 20%-50% ethanol and 20%-50% isopropanol; a solution of about 0.1-4.0 M guanidinium hydrochloride, detergents and up to about 80% ethanol; or a solution of about 80% ethanol.
  • target analytes enter the porous matrix of the ATPS and flow to one end of the porous matrix.
  • target analytes isolated by the present invention are eluted out of the porous matrix using appropriate elution butters or deionized water.
  • isolated target analytes are not eluted but stored for future use in the porous matrix.
  • the porous material e.g. a paper
  • the target analytes e.g. a DNA
  • analytes retained on the porous matrix can be eluted for further analysis or treatment.
  • elution buffer may depend on the contemplated use of the purified biomarker.
  • suitable elution buffers for nucleic acid type of analytes includes, but are not limited to, Tris-EDTA (TE) buffer, aqua bidest and PCR buffer.
  • TE Tris-EDTA
  • the purified analyte on porous paper is eluted in a tube containing TE buffer (10 mM Tris.Cl, 1 mM EDTA solution with pH 7.5), and the purified analyte is recovered in a relatively small volume, e.g., less than 100 ul.
  • Analytes obtained by the present invention can be subject to a wide range of downstream applications such as detection or analysis of the analytes in forensic, diagnostic or therapeutic applications, and laboratory procedures such as sequencing, amplification, reverse transcription, labeling, digestion, blotting procedures and the like. It is expected that the present invention is able to improve the performance of downstream characterization or processing of the analytes.
  • downstream applications of the analyte include, but are not limited to, any detection, analytical or diagnostic procedures involving the detection or quantification of the purified analyte.
  • detection, analytical or diagnostic procedures to be coupled with the present invention include but are not limited to any such procedure performed in commercial clinical laboratory, and laboratory procedures such as sequencing, amplification (e.g. PCR, RT-PCR, real-time PCR, and real-time RT-PCR), reverse transcription, labeling, digestion, blotting procedures, ELISA, RIA, immunoassays, enzymatic assays, GC/MS, proteomic-based approach, and the like.
  • analyte obtained by the present invention can be analyzed by LFA. Diagnostic detection Device
  • the present invention provides a device comprising ATPS as a concentration module linked with a lateral flow immunoassay (LFA) component as a detection module.
  • the detection module is housed in a plastic housing with a viewing window and gold nanoprobes. As the sample wicks up the device and ATPS components undergo phase separation, the analytes are concentrated extremely in the leading front. Concentrated analytes are then detected by the LFA module generating visual test results.
  • the present device is coupled with additional diagnostic assay such as a LFA. The seamless transition between concentration and detection of target analyte will allow a patient or end user to get a test result in one simple single step.
  • the present device is a diagnostic device comprising a LFA detection module and a concentration module comprising ATPS components.
  • LFA Lateral flow immunoassay
  • the ligand and the receptor are related in a way that the receptor specifically binds to the ligand, being capable of distinguishing a specific ligand or ligands from other sample constituents having similar characteristics.
  • Immunological assays involving reactions between antibodies and antigens are one such example of a specific binding assay.
  • Other examples include DNA and RNA hybridization reactions and binding reactions involving hormones and other biological receptors.
  • ATPS components are embedded on a type of pre-coated porous material to create a concentration module for the purpose of integration with the lateral flow immunoassay (LFA).
  • LFA lateral flow immunoassay
  • Figure 7 illustrates one embodiment of the manufacturing process of the present concentration module.
  • Porous material either paper or foam pad of different material types
  • Pre-coated papers were then cut into strips (or other shape) such that there is a pointed tip for easy collection of the concentrated phase.
  • Foam pad materials were cut first prior to treatments.
  • ATPS components are integrated into porous material.
  • a polymer solution (PEG) in DI H 2 0 is added to the narrow end of each of the following porous materials including fiberglass paper, cotton-based paper, proprietary single-layer matrix paper and a polyolefin foam pad.
  • the papers are of the same width but of variable length to account for differences in absorption.
  • a Tris-buffered solution containing protein e.g. bovine serum albumin
  • surfactant Triton X-l 14
  • Tween-20 Tris-buffered solution containing protein (e.g. bovine serum albumin), surfactant (Triton X-l 14) and Tween-20 and PEG polymer is added immediately adjacent to the first solution in certain ratios.
  • the porous material is then placed in a lyophilizer to remove solvent, resulting in embedding the ATPS components directly into the porous material.
  • the papers are cut into 0.5 cm strip lengthwise. Pieces are then stacked together (e.g., 4 strips per stack) and cut at one end from the corner to form a pointed tip for easy collection of concentrated component.
  • This stack is then placed in an indicator-containing buffer solution (e.g., colloidal gold) with salt with varying concentrations of salt (5%, 4.5% and 4% w/w of potassium phosphate in phosphate-buffered solution to achieve concentration factors of 30X, 50X and 100X, respectively. As salt concentration decreases, the concentration factor increases. There is a minimum amount of salt required. That depends on each individual polymer formulation.
  • Figure 8 demonstrates the feasibility of changing the placement and ordering of ATPS components within the concentration module, showing that the pre-coated porous material can be impregnated with both polymer and salt either as separate zones (left) or as one continuous zone where the dehydrated polymer is overlaid on the dehydrated salt (right).
  • the paper is treated in two steps. The first step involves drying salt and polymer in separate zones. This is similar to where different solutions are dried immediately proximal to each other. The second step involves drying the polymer zone in the lyophilizer first, then layering the salt solution directly on top of the dried polymer and dried once more in the lyophilizer for one hour. This approach results in the concentration of analyte.
  • a running buffer containing analyte results in fluid flow and the rehydration of both ATPS components results in concentration of the purple indicator at the tip of the device.
  • the running buffer does not require a predetermined amount of ATPS components, as any liquid sample including urine, saliva, etc. can be used, providing more flexibility for the end user, e.g., patient.
  • a micellar version of the porous material stack identical to the polymer/salt version is made with the exception of the composition of the solution embedded on porous material and the composition of the running solution.
  • concentration factors 40X, 70X and 100X
  • varying amounts and concentrations of surfactant-containing solutions are embedded onto paper. Increasing surfactant concentration leads to a higher concentration factor.
  • phosphate-buffered saline containing indicator is used as the running buffer for all three concentration factors.
  • various porous materials can be used for the concentration module, various designs are used to promote analyte concentration and transfer to the LFA sample pad and test strip. In one embodiment, all these designs can wick large amounts of volume and be optimized for a specific application.
  • ATPS concentration module is designed to promote analyte concentration and transfer to the LFA sample pad and test strip.
  • the design can wick large amounts of sample volume.
  • various porous materials are designed differently for specific applications.
  • the present invention provides stack designs in which multiple porous materials were stacked side-by-side, and solution flowing vertically from the bottom of the stack to the top. The present stack designs are not limited to the detection of S. mutans or assays described herein.
  • one of the key feature of the present invention is the impregnation of porous material with ATPS components in any format such that any sample (urine, saliva, blood, buffer, etc.) will spontaneously phase separate and concentrate/remove the analyte(s) of interest.
  • Streptococcus mutans a bacteria related to the formation of dental caries.
  • Streptococcus mutans S. mutans
  • the concentration is therefore critical for diagnostic test.
  • a 100-fold improvement was achieved in the limit of detection of this bacteria from 10 6 CFU/ml to 10 4 CFU/mL as shown in Figure 5. This is done by using the micellar ATPS embedded directly into pre-coated porous material, and the concentration component was integrated with the LFA test strips.
  • This single-step test can also be used with a polymer/salt ATPS in the same fashion.
  • Figure 5 demonstrates a 100-fold improvement in the limit of detection of S. mutans over the detection using LFA alone.
  • Left panel shows one embodiment of the 3PS device (comprising two-component ATPS for testing, a LFA detection module, a concentration module) used for testing.
  • the LFA detection module is integrated with upstream of the concentration module.
  • Right panel shows the test results using the LFA detection module without the concentration module (top) vs. that of the 3PS device (bottom) at the indicated concentrations of S. mutans.
  • the presence of a control line indicates a valid test, and the presence of a test line indicates a positive result. Test lines are indicated with a black arrowhead. "C" is the control line; "T” is the test line.
  • the diagnostic testing device of this invention can both concentrate and detect an analyte with only a single-step required from the end user.
  • the present invention provides one-step diagnostic device comprising a concentration module of ATPS components and a detection module of LFA test.
  • a diagnostic testing device is provided to concentrate and detect an analyte of interest with only a single-step required from the end user.
  • the present device requires only a single step from the end-user who would apply the specimens onto the analyte collection tip.
  • the ATPS components are attached to analyte collection tip, forming the concentration module.
  • the detection module further comprises a plastic housing.
  • the plastic housing contains a viewing window to show the testing result.
  • the LFA testing module and gold nanoprobes are contained inside the plastic housing.
  • a simple direct junction is formed to connect the concentration module to the detection module. Tape is tightly wound around the intersection between the two modules to hold this junction together and promote flow.
  • said device can be slightly longer and accommodate more sample volume.
  • the specimen wicks up the device and rehydrate the ATPS components. Component separation occurs.
  • the analytes concentrate substantially in the leading front of the flow when flowing into the plastic housing. Concentrated analytes will be conjugated with the gold nanoprobes and detected by the embedded conventional LFA detection module. Visual test results identical to the LFA test will be observed at the viewing window of the plastic housing. By using the present device, the end-user will be able to observe an accurate test result with a single-step.
  • the 3PS device of this invention can be enclosed in cassette housing.
  • the cassette housing in which the 3PS device is enclosed in has many important functions:
  • the 3PS device cassette housing may take a design that is similar to that of a typical LFA test cassette housing. However, because the 3PS device is capable of processing larger volume for an improved concentration fold, its housing dimensions and sample well are larger than typical LFA test cassettes to accommodate the extra size and fluid.
  • integration of the concentration module with LFA creates a new device (3PS) which can handle a seamless transition between concentration and detection, allowing for the end-user to achieve results with a single step.
  • the concentration module can be attached to the LFA in a variety of ways, including with tape, encased in a housing as shown in Figure 9. In one embodiment, the concentration module can be of various sizes to accommodate different volumes of sample.
  • the format of this concentration module can be varied, including the formats shown herein.
  • the present device is a platform device that can be applied to many different applications other than S. mutans detection, including but not limited to detection of chlamydia, malaria, Zika virus, etc.
  • the present invention provides various designs, including two vertically oriented and two horizontally oriented designs. In one design, the design is oriented vertically and is composed of a housing to protect the strip and a separate sample well, which the housing can interlock with to initiate flow (Figure 9A).
  • the device is oriented vertically and is composed of a single integrated housing, where the sample well and housing are inseparable (Figure 9B).
  • the device is oriented horizontally and has a large sample well which is held above the strip ( Figure 9C).
  • the device is also oriented horizontally and has a large sample well which is below the strip, into which the strip is cantilevered (Figure 9D).
  • sample is added to a sample well which is actually under the strip, and the strip is cantilevered into the well to allow for capillary-mediated flow.
  • the present invention provides a device for the concentration and detection of a target analyte in a sample solution, the device comprises:
  • a concentration module connected to said sample well, said module comprising a porous material coated with water soluble nanoparticles and embedded with ATPS (Aqueous Two Phase System) components which form two phase solutions when an aqueous solution travels through said porous material so that one phase solution travels faster than the other, wherein when a sample solution is introduced into the sample well, the porous material will wick said sample solution, wherein the target analyte in the sample solution partitions into the faster moving phase solution and becomes concentrated at the front of the faster moving phase solution; and
  • ATPS Aqueous Two Phase System
  • a detection module connected to said concentration module for detecting the target analyte, said detection module comprising a lateral flow assay and a conjugate pad, wherein the porous material of the concentration module is conjugated with said conjugate pad, wherein the concentrated target analyte flows from said porous material to said conjugate pad and is subsequently analyzed by said lateral flow assay, and wherein a display of color indicates the presence of the target analyte.
  • the nanoparticles are selected from the group consisting of silicon dioxide, iron oxide, titanium dioxide, silver oxide, and any combinations thereof.
  • the porous material is selected from the group consisting of fiber- glass paper, cotton-based paper, single-layer matrix paper and polyolefin foam pad.
  • the ATPS components are selected from polymers, salts and surfactants.
  • the polymers are selected from the group consisting of polyalkylene glycols, poly(oxyalkylene)polymers, poly(oxyalkylene)copolymers, polyvinyl pyrrolidone, polyvinyl alcohol, polyvinyl caprolactam, polyvinyl methylether, alkoxylated surfactants, alkoxylated starches, alkoxylated cellulose, alkyl hydroxyalkyl cellulose, silicone-modified polyethers, poly N-isopropylacrylamide, polyethylene glycol, polypropylene glycol and dextran.
  • the salts are selected from the group consisting of kosmotropic salts, chaotropic salts, inorganic salts having a cation of trimethyl ammonium, triethyl ammonium, tripropyl ammonium, tributyl ammonium, tetramethyl ammonium, tetraethyl ammonium, tetrapropyl ammonium or tetrabutyl ammonium, and an anion of phosphate, sulphate, nitrate, chloride or hydrogen carbonate, NaCl, Na 3 P04, K 3 P0 4 , Na 2 S0 4 , potassium citrate, (NH 4 ) 2 S0 4 , sodium citrate, sodium acetate, ammonium acetate, and any combinations thereof.
  • the surfactants are selected from the group consisting of nonionic surfactants, detergents, Triton-X, Igepal CA-630 and Nonidet P-40.
  • the sample solution contains one or more of blood, plasma, serum, urine, saliva, fecal matters and bodily discharges.
  • the analyte is a DNA, cell-free DNA, circulating tumor DNA, protein, nucleic acid, carbohydrate, lipid, bacterium, virus or nanoparticle.
  • the ATPS components are completely separate or partly overlapping on said porous material.
  • the analyte is concentrated by up to 100-fold.
  • the porous material is in the form of multiple paper strips with one pointed end.
  • the sample solution is a phosphate buffer or a Tris-EDTA buffer with an indicator.
  • the concentration module and the detection module are separable and each in a housing, wherein the device optionally comprises a ring of rubber sealing the connection between the housings.
  • the concentration module and the detection module are inseparable.
  • Example 1- Embedding ATPS on with pre-coated porous material.
  • porous materials including fiberglass paper, cotton-based paper, a proprietary single-layer matrix paper, and a polyolefin foam pad, (of width 2.2 cm and variable length) were soaked separately into the 5M silicon dioxide aqueous solution followed by the vigorous stirring for an hour. The solution was kept at the temperature of 80°C for 24 hours. Then the porous materials were taken out and washed twice with water, and finally dried under compressed air.
  • a pre-coated porous fiberglass paper embedded with ATPS components prepared in Example 1, a blank paper (without ATPS or pre-coating) and a control paper (paper with ATPS but without pre-coating) were dipped in saliva mixture, which was a PBS buffer solution at pH 7.4 and 200 ng/mL of DNA ladder. The papers were wicked for approximately 2 minutes until the solution reached the top.
  • Nitrocellulose membrane was striped with: 1) anti-S. mutans antibody at a concentration of 1 mg/mL, and 2) Protein (Bovine Serum Albumin, BSA) at a concentration of 0.2 mg/mL. Colloidal gold nanoparticles were conjugated to anti-S. mutans antibody as directed by manufacturer instructions. This conjugate was then dried onto conjugate pad material at using a lyophilizer.
  • the sample pad comprised a sample pad material impregnated with a Tris buffer comprising 2% BAS protein, 16% surfactant (Triton X-114), 0.1% PEG polymer, and 20Mm Tris buffer salts.
  • the absorbent pad consisted of untreated paper. To run the LFA test without the concentration module, various materials were assembled on an adhesive backing, the assembly was dipped into solutions containing S. mutans at various concentrations, and the results were analyzed by direct observation.
  • concentration module 300 pL of a surfactant (Triton X-114) solution was added to FG1 pre-coated paper (dimensions 4 cm x 2.2 cm). This piece was subsequently dried in a lyophilizer and cut into 0.5 cm strips lengthwise. These four resulting strips were then stacked to form the concentration module.
  • Triton X-114 Triton X-114
  • mutans concentration of 10 6 CFU/ml the test line was visible, confirming a positive result. However, no test line is visible at 10 4 CFU/ml. In the present 3PS device, no test line was visible for the negative sample, confirming a valid control. At 10 6 CFU/ml, a test line was visible, and the test line intensity was stronger than that of LFA only at 10 6 CFU/ml, confirming that the concentration module successfully concentrated S. mutans and indicating that a concentration fold of about 100 in detecting S. mutans has been achieved. Overall, the result indicated that the present 3PS device was able to detect the bacteria at 10 4 CFU/ml, which was not detectable by LFA alone. The present 3PS device achieved a 100-fold improvement in the limit of detection of S. mutans. References:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une méthode et un dispositif de concentration et de détection d'un analyte cible dans une solution à l'aide d'un matériau poreux revêtu au préalable contenant des constituants d'ATPS incorporés. Selon un mode de réalisation, les nanoparticules hydrosolubles comprennent, sans s'y être limitées, du dioxyde de silicium, de l'oxyde de fer, du dioxyde de titane, de l'oxyde d'argent et n'importe laquelle de leurs combinaisons. Selon un mode de réalisation, la présente invention concerne un dispositif comprenant un ATPS en tant que module de concentration lié à un constituant de dosage immunologique à flux latéral (LFA) en tant que module de détection. Selon un mode de réalisation, lors de la montée par capillarité de l'échantillon dans le dispositif et lorsque les constituants d'ATPS subissent une séparation de phase, les analytes sont concentrés sensiblement dans le front avant, les analytes concentrés sont ensuite détectés par le module de LFA générant des résultats de test visuels. Selon un mode de réalisation, les présents méthode et dispositif servent à détecter des Streptococcus mutans et ainsi des caries dentaires.
PCT/US2018/024779 2017-03-28 2018-03-28 Méthode et dispositif de diagnostic précis de maladies dentaires WO2018183454A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762478021P 2017-03-28 2017-03-28
US62/478,021 2017-03-28

Publications (1)

Publication Number Publication Date
WO2018183454A1 true WO2018183454A1 (fr) 2018-10-04

Family

ID=63676938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/024779 WO2018183454A1 (fr) 2017-03-28 2018-03-28 Méthode et dispositif de diagnostic précis de maladies dentaires

Country Status (2)

Country Link
TW (1) TW201840854A (fr)
WO (1) WO2018183454A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021037075A1 (fr) * 2019-08-27 2021-03-04 Phase Scientific International, Ltd. Procédé, composition et kit d'enrichissement à sélection de taille d'acides nucléiques
US11332796B2 (en) 2018-01-19 2022-05-17 Phase Scientific International, Ltd. Composition and method for concentration and enrichment of nucleic acids
US11366111B2 (en) 2017-03-28 2022-06-21 Phase Scientific International, Ltd. Method for accurate diagnosis of a disease targeting biomarkers in liquid biopsy
US11479765B2 (en) 2018-01-19 2022-10-25 Phase Scientific International, Ltd. Method of isolating exosomes using encapsulation and aqueous micellar system
US11609232B2 (en) 2017-09-01 2023-03-21 Phase Diagnostics, Inc. Method and device of using aqueous two-phase systems (ATPS) for enhancing diagnostics for sexually transmitted infections
US11633676B2 (en) 2017-06-01 2023-04-25 Phase Diagnostics, Inc. Phase separation behavior modifying agents for aqueous two-phase separation within porous material
US11643646B2 (en) 2018-01-19 2023-05-09 Phase Scientific International, Ltd. Method for isolating and purifying nucleic acids using a solid-liquid phase system
US12043826B2 (en) 2018-01-19 2024-07-23 Phase Scientific International, Ltd. Spontaneous nucleic acid purification and concentration in a single step
US12129459B2 (en) 2017-09-18 2024-10-29 Phase Scientific International, Ltd. Method for using aqueous two-phase system for the isolation, purification and/or concentration of short nucleic acid fragments
US12129511B2 (en) 2022-11-02 2024-10-29 Phase Scientific International, Ltd. Methods for isolating target analytes from biological samples using ATPS and solid phase media

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159537A2 (fr) * 2010-06-15 2011-12-22 The Regents Of The University Of California Procédé et dispositif pour la détection d'analytes
US20150253320A1 (en) * 2014-03-07 2015-09-10 The Regents Of The University Of California Methods and devices for integrating analyte extraction, concentration and detection
WO2017041030A1 (fr) * 2015-09-04 2017-03-09 The Regents Of The University Of California Procédés et dispositifs pour la collecte, l'extraction, la concentration, et la détection d'analytes pour des applications cliniques
WO2017214315A1 (fr) * 2016-06-09 2017-12-14 The Regents Of The University Of California Concentration de biomarqueurs et amplification de signaux pour utilisation dans des dosages immunologiques à base de papier et plateforme unique pour extraire, concentrer et amplifier de l'adn
WO2018039139A1 (fr) * 2016-08-22 2018-03-01 The Regents Of The University Of California Plate-forme d'hydrogel pour concentration aqueuse à deux phases d'une cible pour améliorer sa détection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159537A2 (fr) * 2010-06-15 2011-12-22 The Regents Of The University Of California Procédé et dispositif pour la détection d'analytes
US20150253320A1 (en) * 2014-03-07 2015-09-10 The Regents Of The University Of California Methods and devices for integrating analyte extraction, concentration and detection
WO2017041030A1 (fr) * 2015-09-04 2017-03-09 The Regents Of The University Of California Procédés et dispositifs pour la collecte, l'extraction, la concentration, et la détection d'analytes pour des applications cliniques
WO2017214315A1 (fr) * 2016-06-09 2017-12-14 The Regents Of The University Of California Concentration de biomarqueurs et amplification de signaux pour utilisation dans des dosages immunologiques à base de papier et plateforme unique pour extraire, concentrer et amplifier de l'adn
WO2018039139A1 (fr) * 2016-08-22 2018-03-01 The Regents Of The University Of California Plate-forme d'hydrogel pour concentration aqueuse à deux phases d'une cible pour améliorer sa détection

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11366111B2 (en) 2017-03-28 2022-06-21 Phase Scientific International, Ltd. Method for accurate diagnosis of a disease targeting biomarkers in liquid biopsy
US11913948B2 (en) 2017-03-28 2024-02-27 Phase Scientific International, Ltd. Method for accurate diagnosis of a disease targeting biomarkers in liquid biopsy
US11633676B2 (en) 2017-06-01 2023-04-25 Phase Diagnostics, Inc. Phase separation behavior modifying agents for aqueous two-phase separation within porous material
US11938419B2 (en) 2017-06-01 2024-03-26 Phase Diagnostics, Inc. Phase separation behavior modifying agents for aqueous two-phase separation within porous material
US11609232B2 (en) 2017-09-01 2023-03-21 Phase Diagnostics, Inc. Method and device of using aqueous two-phase systems (ATPS) for enhancing diagnostics for sexually transmitted infections
US12129459B2 (en) 2017-09-18 2024-10-29 Phase Scientific International, Ltd. Method for using aqueous two-phase system for the isolation, purification and/or concentration of short nucleic acid fragments
US11332796B2 (en) 2018-01-19 2022-05-17 Phase Scientific International, Ltd. Composition and method for concentration and enrichment of nucleic acids
US11479765B2 (en) 2018-01-19 2022-10-25 Phase Scientific International, Ltd. Method of isolating exosomes using encapsulation and aqueous micellar system
US11643646B2 (en) 2018-01-19 2023-05-09 Phase Scientific International, Ltd. Method for isolating and purifying nucleic acids using a solid-liquid phase system
US12043826B2 (en) 2018-01-19 2024-07-23 Phase Scientific International, Ltd. Spontaneous nucleic acid purification and concentration in a single step
WO2021037075A1 (fr) * 2019-08-27 2021-03-04 Phase Scientific International, Ltd. Procédé, composition et kit d'enrichissement à sélection de taille d'acides nucléiques
US12129511B2 (en) 2022-11-02 2024-10-29 Phase Scientific International, Ltd. Methods for isolating target analytes from biological samples using ATPS and solid phase media

Also Published As

Publication number Publication date
TW201840854A (zh) 2018-11-16

Similar Documents

Publication Publication Date Title
WO2018183454A1 (fr) Méthode et dispositif de diagnostic précis de maladies dentaires
US11913948B2 (en) Method for accurate diagnosis of a disease targeting biomarkers in liquid biopsy
US11938419B2 (en) Phase separation behavior modifying agents for aqueous two-phase separation within porous material
US8614101B2 (en) In situ lysis of cells in lateral flow immunoassays
KR20180052122A (ko) 임상용 분석물 수집, 추출, 농축 및 검출을 위한 방법 및 장치
JPH0560759A (ja) スクシンイミド含有ポリマー由来の生物学的活性試薬の製造方法及びそれを含んでなる分析要素並びにその用途
EP2313775A2 (fr) Lyse in situ de cellules dans des analyses immunologiques à écoulement latéral
Sun et al. Recent progress in aptamer-based microfluidics for the detection of circulating tumor cells and extracellular vesicles
WO2010080978A2 (fr) Appauvrissement préalable en leucocytes dans des échantillons de sang total avant capture des constituants du sang total
EP3625330B1 (fr) Nano-interfaces de synthèse pour l'isolation microfluidique de vésicules extracellulaires
Guo et al. Immunomagnetic separation method integrated with the Strep-Tag II system for rapid enrichment and mild release of exosomes
Lu et al. Evaluation of a new magnetic bead as an integrated platform for systematic CTC recognition, capture and clinical analysis
US20230191283A1 (en) Channeled fibers in separation of biologically active nanoparticles
Malhotra et al. Novel devices for isolation and detection of bacterial and mammalian extracellular vesicles
KR101416344B1 (ko) 막 분석 방법
JP2020511134A (ja) ろ過デバイス、捕捉デバイス、及びそれらの使用
EP3816626A1 (fr) Agencement de test de flux latéral approprié pour la détection d'un analyte dans la salive
JP2008275534A (ja) 標的高分子の精製方法及び検出方法
Romano et al. A comprehensive guide to extract information from extracellular vesicles: a tutorial review towards novel analytical developments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18776986

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18776986

Country of ref document: EP

Kind code of ref document: A1